Sarcoidosis is diagnosed through a combination of imaging, tissue biopsy, and blood tests, not a single definitive test. The process takes an average of nearly 8 months from first symptoms to final diagnosis, largely because sarcoidosis is a diagnosis of exclusion: doctors must rule out infections, occupational exposures, and lymphoma before confirming it. Three criteria need to be met for a diagnosis: symptoms that fit the pattern, evidence of a specific type of inflammation in a tissue sample, and the exclusion of other conditions that look similar.
Chest Imaging: The Usual Starting Point
Most sarcoidosis workups begin with a chest X-ray, since the lungs and lymph nodes in the chest are affected in roughly 90% of cases. Doctors use a staging system based on what the X-ray shows:
- Stage 0: No visible chest abnormality
- Stage I: Enlarged lymph nodes near the lungs (hilar lymphadenopathy) but no lung tissue changes
- Stage II: Enlarged lymph nodes plus abnormalities in the lung tissue itself
- Stage III: Lung tissue abnormalities without enlarged lymph nodes
- Stage IV: Scarring (fibrosis) with loss of lung volume
These stages describe what the X-ray looks like at a single point in time. They don’t necessarily predict how severe the disease will become. A CT scan of the chest often follows, providing more detailed images and helping doctors identify subtle lung changes or lymph node enlargement that a standard X-ray might miss.
Biopsy: Confirming the Diagnosis
The hallmark of sarcoidosis under a microscope is a specific structure called a noncaseating granuloma. These are tiny clusters of immune cells that form in affected tissue. What makes them distinctive is what’s absent: unlike granulomas caused by tuberculosis or fungal infections, sarcoidosis granulomas show no tissue death (necrosis) at their center and no infectious organisms. A pathologist looks for this pattern along with an intact tissue framework to confirm compatibility with sarcoidosis.
The most common way to obtain lung tissue is a procedure called EBUS-TBNA, where a thin, flexible scope is passed through the airway using ultrasound guidance to sample lymph nodes in the chest. This approach has a sensitivity around 88% and a diagnostic accuracy above 90%, and it’s largely replaced older surgical methods because it’s less invasive, has fewer complications, and can be done as an outpatient procedure. In the past, a surgical technique called mediastinoscopy was the standard, requiring a small incision in the neck to access chest lymph nodes. It’s still used occasionally when needle biopsies are inconclusive.
Biopsy doesn’t always have to come from the lungs. If sarcoidosis affects the skin, lymph nodes near the surface, or other accessible organs, doctors may sample those sites instead, since the procedure is simpler and carries less risk. In some cases with a classic presentation on imaging, particularly bilateral hilar lymphadenopathy in a young adult with a condition called Löfgren syndrome, a biopsy may not be required at all.
Blood and Urine Tests
No blood test can confirm sarcoidosis on its own, but several help support the diagnosis and gauge how active the disease is. The most well-known is the serum ACE (angiotensin-converting enzyme) level. Granulomas produce this enzyme, and elevated levels appear in roughly 30% to 80% of sarcoidosis patients. The test’s usefulness is limited, though: its sensitivity ranges from 22% to 86% and its specificity from 54% to 95%, meaning it both misses many true cases and flags some people who don’t have the disease.
Calcium levels in the blood and urine are also checked. The granulomas in sarcoidosis can produce an active form of vitamin D, which drives up calcium absorption. Elevated blood calcium (hypercalcemia) shows up in about 4% to 7% of newly diagnosed patients. While that’s a small minority, finding it in the right clinical context adds another piece to the diagnostic puzzle. Higher levels of the active vitamin D form are also associated with more chronic disease that requires longer treatment.
Other standard blood work typically includes a complete blood count, liver and kidney function tests, and inflammatory markers. These help doctors map which organs might be involved and establish a baseline before treatment.
Breathing Tests
Pulmonary function tests (PFTs) measure how well your lungs move air and transfer oxygen into your blood. In sarcoidosis, the most common pattern is a restrictive one, meaning the lungs can’t fully expand. This shows up in about 45% of patients with lung involvement. Doctors pay close attention to two numbers: your forced vital capacity (FVC), which reflects total lung volume, and your diffusing capacity (DLCO), which measures how efficiently oxygen passes from your lungs into your bloodstream.
An FVC below 70% of predicted or a DLCO below 60% of predicted signals clinically significant lung disease that typically warrants treatment. The ratio of air exhaled in one second to total air exhaled (FEV1/FVC) can also reveal airway obstruction, which occurs in some sarcoidosis patients when granulomas form in or around the airways. These tests don’t diagnose sarcoidosis directly but are essential for tracking its severity and guiding treatment decisions.
Testing for Heart Involvement
Cardiac sarcoidosis is one of the more serious complications and requires its own set of tests. Two advanced imaging methods are used: cardiac MRI and a specialized PET scan.
Cardiac MRI detects scarring in the heart muscle by highlighting areas that absorb a contrast agent called gadolinium. In sarcoidosis, this scarring typically appears in specific locations: just beneath the outer surface of the heart, in the middle of the muscle wall, or at the points where the right ventricle connects to the left. This pattern is distinct from the scarring caused by a heart attack, which tends to follow blood vessel territories. Cardiac MRI has a sensitivity of 93% and a specificity of 85% for diagnosing cardiac sarcoidosis.
The PET scan works differently. It detects active inflammation rather than scarring, which makes it especially useful for deciding whether to start or continue immune-suppressing treatment. The scan requires careful preparation: you’ll need to fast for an extended period and eat a high-fat, low-carbohydrate diet beforehand to suppress normal heart glucose uptake so that only inflamed tissue lights up. Its sensitivity and specificity are around 84% and 83%, respectively. Doctors often use both tests together, since MRI reveals permanent damage while PET shows active disease that might respond to treatment.
Eye Exams
Eye involvement affects more than 75% of sarcoidosis patients and is actually the first symptom in 20% to 30% of cases, making an eye exam an important part of the workup. The most common finding is uveitis, an inflammation of the middle layer of the eye. During a slit-lamp examination, an ophthalmologist looks for several telltale signs: inflammatory deposits on the inner surface of the cornea (called keratic precipitates, which in sarcoidosis tend to be large and “mutton-fat” in appearance), inflammatory cells floating in the fluid at the front of the eye, and adhesions between the iris and the lens that cause an irregularly shaped pupil.
Looking deeper into the eye, doctors may find inflammation of the optic nerve or inflammation around the veins of the retina. Some of these signs, like an irregularly shaped pupil, can be spotted without magnification, but a full slit-lamp exam is needed to catch subtler findings. Even if you have no eye symptoms, a baseline eye exam is typically part of a sarcoidosis evaluation because inflammation can be present without causing noticeable vision changes early on.
Why Diagnosis Takes So Long
The average diagnostic delay of nearly 8 months reflects several real challenges. Sarcoidosis can mimic infections, cancers, and autoimmune diseases, and there’s no single test that rules it in or out. Symptoms vary wildly depending on which organs are affected, so patients often see multiple specialists before anyone connects the dots. One review found that the first doctor consulted ranged from a general practitioner to an emergency physician to a gynecologist or oncologist, depending on how the disease presented.
Getting a tissue biopsy also adds time. Scheduling the procedure, waiting for pathology results, and sometimes repeating biopsies when results are inconclusive all contribute. Relying too heavily on chest X-rays alone, without moving to CT or biopsy, is another documented source of delay. The lack of a standardized diagnostic protocol means the process can vary significantly from one hospital or specialist to another.